A Phase 2a, Open-Label, Multicenter, Activity and Safety Study of KX2-391 Ointment in Subjects With Actinic Keratosis on the Face or Scalp
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
At a glance
- Drugs KX 01 (Primary)
- Indications Actinic keratosis
- Focus Therapeutic Use
- Sponsors Athenex
- 14 Aug 2017 According to Athenex Inc.media release, data release from this trial is expected in second half of 2017.
- 01 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 17 Dec 2015 New trial record